pharma · Peripheral T Cell Lymphoma
Zhao Weili
Zhao Weili is a pharma organization headquartered in CN. Primary therapeutic focus areas include Peripheral T Cell Lymphoma. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this e
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 3
- Patents
- 0
CAR-T Therapy
Phase 1 · small molecule · Peripheral T Cell Lymphoma
CAR-T Therapy for Peripheral T Cell Lymphoma is a Phase 1 program (small_molecule) at Zhao Weili with 1 ClinicalTrials.gov record(s).
Internal code BHCT-RD13-02P
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Zhao Weili
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Peripheral T Cell Lymphoma
- Status
- active
- Trials
- 1